Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.75 |
| ▸ | MMP9 | P14780 | 13/20 | 0.75 |
| ▸ | ADAM17 | P78536 | 11/20 | 0.75 |
| ▸ | MMP1 | P03956 | 10/20 | 0.60 |
| ▸ | MMP3 | P08254 | 3/20 | 0.55 |
| ▸ | MMP7 | P09237 | 3/20 | 0.55 |
| ▸ | MMP8 | P22894 | 3/20 | 0.55 |
| ▸ | MMP13 | P45452 | 3/20 | 0.55 |
| ▸ | MMP14 | P50281 | 3/20 | 0.55 |
| ▸ | ADAM33 | Q9BZ11 | 2/20 | 0.55 |
| ▸ | MMP15 | P51511 | 1/20 | 0.55 |
| ▸ | MMP16 | P51512 | 1/20 | 0.55 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628657 | 0.87 | MMP2 (0.78) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628455 | 0.86 | MMP9 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL8049741 | 0.86 | MMP2 (0.54) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628166 | 0.85 | MMP2 (0.74) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6626999 | 0.83 | MMP2 (0.84) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628135 | 0.83 | MMP2 (0.70) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628975 | 0.77 | MMP2 (0.79) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6627729 | 0.77 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628712 | 0.76 | MMP2 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6628034 | 0.76 | MMP9 (0.66) | MMP2MMP9ADAM17MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | claimed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | claimed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | claimed |
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | MMP2 10/4885MMP9 5/4885ADAM17 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.